Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 4, 1997, Pages 506-508

  Serot, J M ^a,b   Christmann, D ^a   Dubost, T ^a   Couturier, M ^a  

^a Hotel Dieu   (France)

^b NONE

Author keywords

Aging; Alzheimer's; Cerebrospinal fluid; Disease; Transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; PREALBUMIN;

ADOLESCENT; ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCHOOL CHILD;

EID: 0030864769     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.4.506     Document Type: Article

References (23)

1. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994;14:495-533.
2. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ. Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 1996;204:212-4.
3. Schwarzman AL, Gregori L, Vitek MP, Luybski S, Strittmatter WJ, Engehilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Goldgaber D. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc Natl Acad Sci 1994;91:8368-72.
4. Riisøen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 1988;78:455-9.
5. McKahn G, Drachman D, Folstein M, Katzmann R, Price D, Stadlan EM. Clinical diagnosis of Alzheimeris disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34: 939-44.
6. Kleine TO, Hackler R, Dauch W, Zöfel P. Transport and production of cerebrospinal fluid (CSF) change in aging humans under normal and diseased conditions. Z Gerontol 1993;26:251-5.
7. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992;4:226-60.
8. Pantoni L, Inzitari D, Pracucci G, Lolli F, Giordano GP, Bracco L, Amaducci L. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993;115:125-31.
9. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid is reduced in healthy aging. Neurology 1990;40:500-3.
10. Shuanghoti S, Netsky MG. Human choroid plexus: morphologic and histochemical alterations with age. Am J Anat 1970;128:73-96.
11. Serot JM, Béné MC, Foliguet B, Faure GC. Altered choroid plexus basement membrane and epithelium in late-onset Alzheimer disease: an ultrastructural study. Ann N-Y Acad Sci 1997 (in press).
12. Zheng W, Shen H, Blaner WS, Zhao Q, Ren X, Graziano JH. Chronic lead exposure alters transthyretin concentration in rat cerebrospinal fluid: the role of the choroid plexus. Toxicol Appl Pharmacol 1996;139:445-50
13. Ikeda T, Furukawa Y, Mashimoto S, Takahashi K, Yamada M. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Psychiatr Scand 1990;82:327-9.
14. Brusa G, Claudiani F, Piccardo A, Pizio N, Stoeh R. Scinticysternography in presenile and senile degenerative disease. Ital J Neurol Sci 1990;11:43-7.
15. Jellinger K. Neuropathological aspects of dementias resulting from abnormal blood and cerebrospinal fluid dynamics. Acta Neurol Belg 1976;76:83-102.
16. Wisniewski T, Castano E, Ghiso J, Frangione B. Cerebrospinal fluid inhibits β amyloid fibril formation in vitro. Ann Neurol 1993;34:631-3.
17. Aksenova MV, Aksenov NY, Butterfield DA, Carney JM. Alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci Lett 1996;211:45-8.
18. Fraser PE, Nguhen GT, McLachlan DR, Abraham CR, Kirschner D. α1-Antichymotrypsin binding to Alzheimer's A β peptides is sequence specific and induces fibril disaggregation. J Neurochem 1993;61:298-306.
19. Ladu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to β amyloid. J Biol Chem 1995;270:9039-42.
20. Golabek AA, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid β peptide is dependent on β peptide conformation. J Biol Chem 1996;271:10602-6.
21. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A β interaction. J Biol Chem 1995;270:7563-7.
22. Schwarzman AL, Goldgaber D. Interaction of transthyretin with amyloid β-protein: binding and inhibition of amyloid formation. In: Bock GR, Goode JA, eds. The nature and origin of amyloid fibrils. Chichester: Wiley (Ciba Foundation Symposium 199), 1996:146-64.
23. van Gool WA, Schenk DB, Bolhuis PA. Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease. Neurosci Lett 1994;172:122-4.